Bank of America Corp DE Has $1.08 Million Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Bank of America Corp DE trimmed its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 80.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,848 shares of the biopharmaceutical company's stock after selling 175,590 shares during the period. Bank of America Corp DE owned approximately 0.06% of Celldex Therapeutics worth $1,083,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Invesco Ltd. raised its position in Celldex Therapeutics by 2.1% in the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after purchasing an additional 871 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 878 shares during the last quarter. Swiss National Bank raised its position in Celldex Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock worth $2,964,000 after purchasing an additional 1,400 shares during the last quarter. KBC Group NV raised its position in Celldex Therapeutics by 79.1% in the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 1,647 shares during the last quarter. Finally, MetLife Investment Management LLC raised its position in Celldex Therapeutics by 6.1% in the 4th quarter. MetLife Investment Management LLC now owns 39,620 shares of the biopharmaceutical company's stock worth $1,001,000 after purchasing an additional 2,288 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently commented on CLDX shares. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Morgan Stanley dropped their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. UBS Group dropped their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $53.90.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX traded down $0.64 during midday trading on Monday, reaching $20.71. 851,199 shares of the stock were exchanged, compared to its average volume of 918,377. The business has a 50-day simple moving average of $18.98 and a two-hundred day simple moving average of $21.95. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -8.06 and a beta of 1.33. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.